Top View
- Molecular Profiling in Small Cell Lung Cancer and Lung Neuroendocrine Tumors
- Novel Tumor-Specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-Regulated Kinase Activity
- Emerging Oncogenic Fusions Other Than ALK, ROS1, RET, and NTRK in NSCLC and the Role of Fusions As Resistance Mechanisms to Targeted Therapy
- Next-Generation Sequencing Analysis of Receptor-Type Tyrosine Kinase
- Original Article a RTK-Based Functional Rnai Screen Reveals Determinants of PTX-3 Expression
- Brigatinib Overcomes ALK Resistance Mechanisms Preclinically Zhang Et Al
- A Wonder Drug for Targeted Cancer Therapy in Non-Small Cell Lung Cancer ⇑ Silky Bedi A, Shah A
- HTG Edgeseq PATH Assay Gene List
- Amoydx ALK Gene Fusions and ROS1 Gene Fusions Detection
- Kinase Fusions Are Frequent in Spitz Tumours and Spitzoid Melanomas
- Xt GENE PANEL
- Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
- Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030
- Incidence of ERBB Gene Fusions (EGFR, ERBB2, ERBB4) Across Tumor Types Laura Schubert1, Andrew Elliott2, Robert C
- High Throughput Kinase Discovery, Inhibitor Screening and Specificity Analysis Using Multi-Array Technology
- This Is an Author Produced Version of a Paper Published in Current Drug Targets
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Coexistent Genetic Alterations Involving ALK, RET, ROS1 Or MET
- The Race to Target MET Exon 14 Skipping Alterations in Non-Small Cell
- Oncomine Dx Target Test—The Right Choice for Your Patients
- Exploiting Insights on the RET Receptor for Personalized Cancer Medicine
- WO 2017/037220 Al 9 March 2017 (09.03.2017) P O P C T
- MET Exon 14 Skipping Alterations in Non-Small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances
- Molecular Biomarkers for Lung Adenocarcinoma
- NTRK, RET, ROS1, and ALK Gene Fusion in HER2 Immunohistochemistry 2+ Breast Carcinoma
- Foretinib Is a Potent Inhibitor of Oncogenic ROS1 Fusion Proteins
- RET, NTRK, EGFR and BRAF Gene Rearrangements in Non-Small Cell Lung Cancer
- ALK) Mutations in Neuroblastoma
- Title: Molecular Pathways ‐ ROS1 Fusion Proteins in Cancer
- ALK and ROS1 As Targeted Therapy Paradigms and Clinical Implications to Overcome Crizotinib Resistance
- Rare but Recurrent ROS1 Fusions Resulting from Chromosome 6Q22 Microdeletions Are Targetable Oncogenes in Glioma
- Solid Tumor Profile Plus (Breast Cancer)
- Clinical Genomic Pro Ling to Identify Actionable Alterations for Very Early
- PF-06463922 Is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1 Mutations
- Human Ribonuclease 1 Serves As a Secretory Ligand of Ephrin A4 Receptor and Induces Breast Tumor Initiation
- Oncology Gene List
- AXL Receptor Tyrosine Kinase As a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
- Expression of C-Terminal ALK, RET, Or ROS1 in Lung Cancer Cells with Or
- Immunohistochemical Expression of ROS-1 in Mammary Ductal Carcinoma in Correlation with Hormonal Receptor Status and Her2neu Expression
- Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-Small Cell Lung Cancer
- Role and Targeting of Anaplastic Lymphoma Kinase in Cancer
- Resistance Mechanisms and Potent-Targeted Therapies of ROS1
- ROS1 Polyclonal ANTIBODY Catalog Number:26960-1-AP
- The Role of the Respiratory Syncytial Virus Fusion
- Crizotinib in MET Deregulated Or ROS1 Rearranged Pretreated Non
- Resistance Mechanisms to Targeted Therapies in ROS1 and ALK Non
- ROS1, Active ROS1, Active
- Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine
- Outcomes of Pemetrexed-Based Chemotherapies in HER2-Mutant
- Advances in Targeting RET-Dependent Cancers
- Active Kinase Manual
- ABOUT LORLATINIB ALK in NSCLC ROS1 in NSCLC PRECLINICAL
- Supplementary Table 1. a Full List of Cancer Genes
- Lung Cancer (NSCLC), ROS1 (6Q22) Rearrangement, FISH
- Gene Symbol AATYK AATYK2 AATYK3 ALK AXL CSF1R DDR1
- Ephrin and Eph-Receptor Growth Factor Signaling in Non Small Cell Lung Cancer –Identification of Biomarkers and Therapeutic Targets
- Tyrosine Kinase Receptors in Oncology
- Myeloid Innate Immunity Human Vapril2018
- EPHA Mutation As a Predictor of Immunotherapeutic Efficacy in Lung Adenocarcinoma